About: Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.63 (+21.05%)
GLMDNASDAQGalmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd share price
GLMD price activity
Último preço
$ 4,630
Variação (24h)
0,81 USD (21,05%)
Volume
290.36K
Volume (média 4 sem.)
-
Abertura
$ 3,91
Variação do dia
$ 3,82 - $ 4,63
Fechamento anterior
$ 3,83
Último negócio
09 Sep, 8:22 pm GMT+0
Atrasado
09 Sep, 8:22 pm GMT+0
GLMD price performance
Atrasado
09 Sep, 8:22 pm GMT+0
quote.marketSignals